Question

On January 4, 2018, Runyan Bakery paid $324 million for 10 million shares of Lavery Labeling...

On January 4, 2018, Runyan Bakery paid $324 million for 10 million shares of Lavery Labeling Company common stock. The investment represents a 30% interest in the net assets of Lavery and gave Runyan the ability to exercise significant influence over Lavery's operations. Runyan chose the fair value option to account for this investment. Runyan received dividends of $2.00 per share on December 15, 2018, and Lavery reported net income of $160 million for the year ended December 31, 2018. The market value of Lavery's common stock at December 31, 2018, was $31 per share. On the purchase date, the book value of Lavery's net assets was $800 million and:

The fair value of Lavery's depreciable assets, with an average remaining useful life of six years, exceeded their book value by $80 million.

The remainder of the excess of the cost of the investment over the book value of net assets purchased was attributable to goodwill.


Required:
1-a. Prepare all appropriate journal entries related to the investment during 2018, assuming Runyan accounts for this investment under the fair value option, and accounts for the Lavery investment in a manner similar to what it would use for securities for which there is not significant influence.

(Record the purchase of Lavery Labeling stock for $324 million)

( Record Runyan Bakery's share of Lavery's $160 million net income)

(Record the receipt of cash dividends of $2 per share on 10 million shares)

(Record any necessary entry related to depreciation. The fair value of Lavery's depreciable assets, with an average remaining useful life of six years, exceeded their book value by $80 million)

(Record any necessary adjusting entry to correctly report the investment on the balance sheet. The market value of Lavery's common stock at December 31, 2018 was $31 per share)

Homework Answers

Know the answer?
Your Answer:

Post as a guest

Your Name:

What's your source?

Earn Coins

Coins can be redeemed for fabulous gifts.

Not the answer you're looking for?
Ask your own homework help question
Similar Questions
On January 4, 2018, Runyan Bakery paid $336 million for 10 million shares of Lavery Labeling...
On January 4, 2018, Runyan Bakery paid $336 million for 10 million shares of Lavery Labeling Company common stock. The investment represents a 30% interest in the net assets of Lavery and gave Runyan the ability to exercise significant influence over Lavery's operations. Runyan received dividends of $2.50 per share on December 15, 2018, and Lavery reported net income of $210 million for the year ended December 31, 2018. The market value of Lavery's common stock at December 31, 2018,...
On January 4, 2021, Runyan Bakery paid $326 million for 10 million shares of Lavery Labeling...
On January 4, 2021, Runyan Bakery paid $326 million for 10 million shares of Lavery Labeling Company common stock. The investment represents a 30% interest in the net assets of Lavery and gave Runyan the ability to exercise significant influence over Lavery's operations. Runyan received dividends of $3.50 per share on December 15, 2021, and Lavery reported net income of $160 million for the year ended December 31, 2021. The market value of Lavery's common stock at December 31, 2021,...
On January 4, 2018, Runyan Bakery paid $354 million for 10 million shares of Lavery Labeling...
On January 4, 2018, Runyan Bakery paid $354 million for 10 million shares of Lavery Labeling Company common stock. The investment represents a 30% interest in the net assets of Lavery and gave Runyan the ability to exercise significant influence over Lavery's operations. Runyan received dividends of $2.30 per share on December 15, 2018, and Lavery reported net income of $300 million for the year ended December 31, 2018. The market value of Lavery's common stock at December 31, 2018,...
On January 4, 2021, Runyan Bakery paid $342 million for 10 million shares of Lavery Labeling...
On January 4, 2021, Runyan Bakery paid $342 million for 10 million shares of Lavery Labeling Company common stock. The investment represents a 30% interest in the net assets of Lavery and gave Runyan the ability to exercise significant influence over Lavery's operations. Runyan received dividends of $3.50 per share on December 15, 2021, and Lavery reported net income of $240 million for the year ended December 31, 2021. The market value of Lavery's common stock at December 31, 2021,...
Fizer Pharmaceutical paid $81 million on January 2, 2021, for 3 million shares of Carne Cosmetics...
Fizer Pharmaceutical paid $81 million on January 2, 2021, for 3 million shares of Carne Cosmetics common stock. The investment represents a 20% interest in the net assets of Carne and gave Fizer the ability to exercise significant influence over Carne’s operations. Fizer received dividends of $2 per share on December 21, 2021, and Carne reported net income of $40 million for the year ended December 31, 2021. The fair value of Carne’s common stock at December 31, 2021, was...
Change to Equity Method On January 1, 2018, Lion Company paid $600,000 for 10,000 shares of...
Change to Equity Method On January 1, 2018, Lion Company paid $600,000 for 10,000 shares of Wolf Company's voting common stock, which was a 10% interest in Wolf. Lion does not have the ability to exercise significant influence over the operating and financial policies of Wolf. Lion received dividends of $1.00 per share from Wolf on October 2, 2018. Wolf reported net income of $400,000 for the year ended December 31, 2018, and the ending market price of its shares...
On January 2, 2018, Miller Properties paid $30 million for 1 million shares of Marlon Company's...
On January 2, 2018, Miller Properties paid $30 million for 1 million shares of Marlon Company's 6 million outstanding common shares. Miller's CEO became a member of Marlon's board of directors during the first quarter of 2018. The carrying amount of Marlon's net assets was $127 million. Miller estimated the fair value of those net assets to be the same except for a patent valued at $30 million above cost. The remaining amortization period for the patent is 10 years....
On January 2, 2018, Miller Properties paid $18 million for 1 million shares of Marlon Company's...
On January 2, 2018, Miller Properties paid $18 million for 1 million shares of Marlon Company's 6 million outstanding common shares. Miller's CEO became a member of Marlon's board of directors during the first quarter of 2018. The carrying amount of Marlon's net assets was $67 million. Miller estimated the fair value of those net assets to be the same except for a patent valued at $30 million above cost. The remaining amortization period for the patent is 10 years....
Assume that, on January 1, 2018, Sosa Enterprises paid $3,000,000 for its investment in 60,000 shares...
Assume that, on January 1, 2018, Sosa Enterprises paid $3,000,000 for its investment in 60,000 shares of Orioles Co. Further, assume that Orioles has 120,000 total shares of stock issued and estimates an eight-year remaining useful life and straight-line depreciation with no residual value for its depreciable assets. At January 1, 2018, the book value of Orioles' identifiable net assets was $7,000,000, and the fair value of Orioles was $10,000,000. The difference between Orioles' fair value and the book value...
Assume that, on January 1, 2021, Sosa Enterprises paid $2,240,000 for its investment in 30,000 shares...
Assume that, on January 1, 2021, Sosa Enterprises paid $2,240,000 for its investment in 30,000 shares of Orioles Co. Further, assume that Orioles has 100,000 total shares of stock issued and estimates an eight-year remaining useful life and straight-line depreciation with no residual value for its depreciable assets. At January 1, 2021, the book value of Orioles' identifiable net assets was $7,260,000, and the fair value of Orioles was $10,000,000. The difference between Orioles' fair value and the book value...
ADVERTISEMENT
Need Online Homework Help?

Get Answers For Free
Most questions answered within 1 hours.

Ask a Question
ADVERTISEMENT